GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Cyclically Adjusted Price-to-FCF

Sorrento Therapeutics (FRA:8STN) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sorrento Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Sorrento Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.11/128.7287*128.7287
=-0.110

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 -0.192 98.790 -0.250
201312 -0.262 98.326 -0.343
201403 -0.289 99.695 -0.373
201406 -0.189 100.560 -0.242
201409 -0.159 100.428 -0.204
201412 -0.214 99.070 -0.278
201503 -0.235 99.621 -0.304
201506 0.028 100.684 0.036
201509 -0.473 100.392 -0.607
201512 -0.435 99.792 -0.561
201603 -0.492 100.470 -0.630
201606 -0.264 101.688 -0.334
201609 -0.316 101.861 -0.399
201612 -0.318 101.863 -0.402
201703 -0.479 102.862 -0.599
201706 -0.283 103.349 -0.352
201709 -0.166 104.136 -0.205
201712 -0.472 104.011 -0.584
201803 -0.233 105.290 -0.285
201806 -0.208 106.317 -0.252
201809 -0.173 106.507 -0.209
201812 -0.364 105.998 -0.442
201903 -0.359 107.251 -0.431
201906 -0.328 108.070 -0.391
201909 -0.310 108.329 -0.368
201912 -0.206 108.420 -0.245
202003 -0.191 108.902 -0.226
202006 -0.157 108.767 -0.186
202009 -0.223 109.815 -0.261
202012 -0.065 109.897 -0.076
202103 -0.141 111.754 -0.162
202106 -0.235 114.631 -0.264
202109 -0.239 115.734 -0.266
202112 -0.213 117.630 -0.233
202203 -0.232 121.301 -0.246
202206 -0.197 125.017 -0.203
202209 -0.145 125.227 -0.149
202212 -0.147 125.222 -0.151
202303 -0.099 127.348 -0.100
202306 -0.110 128.729 -0.110

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sorrento Therapeutics  (FRA:8STN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (FRA:8STN) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines